PTC Therapeutics
PTCT
65 hedge funds and large institutions have $600M invested in PTC Therapeutics in 2014 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 13 closing their positions.
191% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 11
129% more capital invested
Capital invested by funds: $262M → $600M (+$338M)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
25.56% more ownership
Funds ownership: 50.76% → 76.32% (+26%)
7% more funds holding
Funds holding: 61 → 65 (+4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.4M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$24.2M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$23.9M |
| 4 |
O
OrbiMed
New York
|
+$22.3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$12.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.79M |
| 3 |
DM
Deerfield Management
New York
|
-$6.11M |
| 4 |
Jennison Associates
New York
|
-$4.41M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$2.33M |
PTCT Hedge Fund Activity: Q1 2014 in Review
65 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2014, worth a combined $600M — up 129% from $262M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PTCT positions and 13 closed out — a net gain of 5 holders — while 32 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $65.4M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $12.8M sold.
- 65 institutional investors held PTC Therapeutics (PTCT) as of Q1 2014, up from 61 in Q4 2013.
- Funds reported $600M of PTC Therapeutics stock for Q1 2014, up 129% quarter-over-quarter.
- 18 funds opened new PTC Therapeutics positions in Q1 2014 and 13 closed out, a net change of +5 holders.
- The largest PTC Therapeutics buyer in Q1 2014 was Fidelity Investments, an estimated $65.4M added.
- The largest PTC Therapeutics seller in Q1 2014 was Novo Holdings A/S, an estimated $12.8M sold.
Based on aggregated 13F filings for Q1 2014.